Skip to main content

Health technology leader Philips recognized as Clarivate Top 100 Global Innovator

Written by Customer Service on . Posted in Public Companies.

Azurion neuro biplane

Philips BlueSeal MRI Magnet

Philips HealthSuite Imaging

EPIQ Elite ultrasound system

March 6, 2024

Company’s innovative products and solutions improved the lives of 1.9 billion people in 2023

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has been included in the 2024 Clarivate Top 100 Global Innovator™ list. Philips’ global R&D programs and collaborations aim to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Together with healthcare providers and other ecosystem partners, Philips co-creates innovations that increase access to healthcare globally and create sustainable and resilient healthcare models.

For example, illustrating the global reach of its efforts to accelerate more productive and sustainable MR imaging operations, Philips has installed more than 1,000 MR systems with its virtually helium-free BlueSeal magnet, which requires only 0.5% of the helium of a conventional Philips MR system. Additionally, Philips recently launched its new Azurion image-guided therapy system and advanced informatics to enhance the minimally invasive diagnosis and treatment of neurovascular patients and reduce the time clinicians require per patient.

Roy Jakobs, CEO of Royal Philips said: “At Philips, we’ve been innovating to improve lives for over 130 years. People’s needs are at the very heart of how we innovate and design for sustainable impact with a ‘safety and quality first’ mindset. Innovation is our core strength and will continue to be our core differentiator. Recent industry trends have accelerated the adoption of technology within healthcare. We are embracing these trends and shifting our innovation to a more patient- and people-centric model closer to our customers.”

Further examples of innovations that help clinicians increase productivity and save time include Philips’ recently introduced next-generation EPIQ Elite and Affiniti ultrasound systems with AI and expanded tele-ultrasound capability, and Philips’ recently launched Philips HealthSuite Imaging, a cloud-based Picture Archiving and Communication System with high-speed remote access for diagnostic reading and AI-enabled workflow orchestration.

The Top 100 Global Innovators uses a comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. Philips has now been included in this reputable list for eleven consecutive years and is the highest ranked company in the ‘Medical and biotechnology’ industry in the 2024 report. The full report can be found here.

For further information, please contact:

Ben Zwirs
Philips External Relations
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.